Nephrocare Health Services delivered strong growth with sales rising 32% YoY to Rs. 260 crore, reflecting expansion momentum in healthcare services. EBITDA increased 38% YoY to Rs. 60.9 crore, indicating healthy operating performance despite cost pressures. Net profit jumped 60% YoY to Rs. 32.2 crore, marking a sharp turnaround from the previous quarterβs loss. However, EPS declined sharply on a YoY basis, suggesting possible equity dilution or accounting adjustments. The numbers highlight robust growth, but valuation remains elevated at 74.8x PE.
π GMP | Reviews | Subscription | Allotment
π Chanakya Grey Market Intelligence - 8 PM EditionΒ | Sahifund |Β
π Power Calls | Breakout Stocks | Coffee Can Portfolio |Β
